

# Juliette Sheridan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2405129/publications.pdf>

Version: 2024-02-01

18  
papers

227  
citations

1040056

9  
h-index

996975

15  
g-index

18  
all docs

18  
docs citations

18  
times ranked

512  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reduced Serological Response to COVID-19 Vaccines in Patients with IBD is Further Diminished by TNF Inhibitor Therapy; Early Results of the VARIATION study [VARIability in Response in IBD Against SARS-COV-2 Immunisation]. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1354-1362.	1.3	15
2	THE USE OF HYOSCINE BUTYLBROMIDE IMPROVES SESSILE SERRATED LESION DETECTION. <i>Endoscopy</i> , 2022, 54, .	1.8	1
3	IMPLEMENTATION OF BOTH BSG 2019 AND ESGE 2020 POLYPECTOMY SURVEILLANCE GUIDELINES SAFELY REDUCES THE BURDEN OF SURVEILLANCE IN A SCREENING COHORT – A VIRTUAL MODEL STUDY. <i>Endoscopy</i> , 2022, 54, .	1.8	0
4	The effect of sedation on EGD inspection time. <i>Gastrointestinal Endoscopy</i> , 2021, 94, 875-876.	1.0	1
5	Comparison of medium to long-term outcomes of acute severe ulcerative colitis patients receiving accelerated and standard infliximab induction. <i>Frontline Gastroenterology</i> , 2020, 11, 441-447.	1.8	6
6	Protocol for a multicentred randomised controlled trial investigating the use of personalised golimumab dosing tailored to inflammatory load in ulcerative colitis: the GOAL-ARC study (GLM dose) <i>Tj ETQq0 0 0,rgBT /Overlock 10 Tf</i>	2.7	9
7	CRP/Albumin Ratio. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, e48-e52.	2.2	64
8	Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: a pilot study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 333-339.	3.7	14
9	Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1019-1026.	1.6	9
10	Increased non-melanoma skin cancer risk in young patients with inflammatory bowel disease on immunomodulatory therapy: a retrospective single-centre cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 978-985.	2.4	16
11	Letter: vedolizumab for the management of inflammatory bowel disease in patients after liver transplantation for primary sclerosing cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 376-378.	3.7	12
12	Editorial: gut selective immunosuppression – is it a double edged sword?. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 373-373.	3.7	3
13	P261 Grading post-operative recurrence in Crohn's disease: a comparison between MRE and ileocolonoscopy. <i>Journal of Crohn's and Colitis</i> , 2017, 11, S210-S210.	1.3	2
14	P578 Evolution of Crohn's disease treatment in clinical practice: a 25 year single centre cohort study. <i>Journal of Crohn's and Colitis</i> , 2017, 11, S375-S375.	1.3	0
15	Letter: Vedolizumab in Pregnancy. <i>Journal of Crohn's and Colitis</i> , 2016, 11, jjw214.	1.3	7
16	Determinants of short- and long-term survival from colorectal cancer in very elderly patients. <i>Journal of Geriatric Oncology</i> , 2014, 5, 376-383.	1.0	14
17	Effects of Radiation on Levels of DNA Damage in Normal Non-adjacent Mucosa from Colorectal Cancer Cases. <i>Journal of Gastrointestinal Cancer</i> , 2013, 44, 41-45.	1.3	10
18	Nuclear oxidative damage correlates with poor survival in colorectal cancer. <i>British Journal of Cancer</i> , 2009, 100, 381-388.	6.4	44